Compare
USANA Health Sciences Inc vs biote Corp. vs Cronos Group Inc. vs Natural Alternatives International Inc
| Latest fiscal year | USANA Health Sciences Inc USNA | biote Corp. BTMD | Cronos Group Inc. CRON | Natural Alternatives International Inc NAII |
|---|---|---|---|---|
| Year ended | 2026-01-03 | 2025-12-31 | 2025-12-31 | 2025-06-30 |
| Revenue | $925.26M | $192.22M | $146.59M | $129.86M |
| Revenue growth (YoY) | +8.3% | -2.5% | +24.6% | +14.1% |
| Gross margin | 78.3% | n/a | 42.8% | 7.2% |
| Operating margin | 4.0% | 18.5% | -11.9% | -6.7% |
| Net margin | 1.2% | 14.1% | -6.4% | -10.5% |
| Net income | $10.76M | $27.05M | -$9.45M | -$13.57M |
| EPS (Diluted) | $0.58 | $0.74 | -$0.02 | -$2.28 |
| Operating cash flow | $22.35M | $35.19M | $25.87M | $5.93M |
| Free cash flow | $8.53M | $30.18M | $149.0K | $2.32M |
| Cash & equivalents | $158.38M | $24.12M | $791.79M | $12.32M |
| Total assets | $742.91M | $107.61M | $1.20B | $151.94M |
| Total liabilities | $156.64M | $158.01M | $54.18M | $83.51M |
| Shareholders' equity | $533.10M | -$58.54M | $1.14B | $68.43M |
| Return on year-end equity | 2.0% | n/a | -0.8% | -19.8% |
| Shares outstanding | 18.28M | n/a | 381.59M | 6.18M |
Revenue, most recent five fiscal years
| Fiscal year | USANA Health Sciences Inc | biote Corp. | Cronos Group Inc. | Natural Alternatives International Inc |
|---|---|---|---|---|
| Latest | $925.26M Ended 2026-01-03 | $192.22M Ended 2025-12-31 | $146.59M Ended 2025-12-31 | $129.86M Ended 2025-06-30 |
| 1 year earlier | $854.50M Ended 2024-12-28 | $197.19M Ended 2024-12-31 | $117.61M Ended 2024-12-31 | $113.80M Ended 2024-06-30 |
| 2 years earlier | $921.01M Ended 2023-12-30 | $185.36M Ended 2023-12-31 | $87.24M Ended 2023-12-31 | $154.01M Ended 2023-06-30 |
| 3 years earlier | $998.60M Ended 2022-12-31 | $164.96M Ended 2022-12-31 | $86.75M Ended 2022-12-31 | $170.97M Ended 2022-06-30 |
| 4 years earlier | $1.19B Ended 2022-01-01 | $139.40M Ended 2021-12-31 | $64.56M Ended 2021-12-31 | $178.52M Ended 2021-06-30 |